Details
Stereochemistry | ACHIRAL |
Molecular Formula | Sb |
Molecular Weight | 121.76 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Sb]
InChI
InChIKey=OUULRIDHGPHMNQ-UHFFFAOYSA-N
InChI=1S/Sb.3H
Antimony (Sb) is a toxic metalloid that occurs widely at trace concentrations in soil, aquatic systems, and the atmosphere. Antimony is not an abundant element but is found in small quantities in over 100 mineral species. It is most often found as antimony(III) sulfide. Antimony is used in the electronics industry to make some semiconductor devices, such as infrared detectors and diodes. It is alloyed with lead or other metals to improve their hardness and strength. A lead-antimony alloy is used in batteries. Other uses of antimony alloys include type metal (in printing presses), bullets and cable sheathing. Antimony has been in medical use against microbes and parasites as well. Antimony-based drugs have been prescribed against leishmaniasis since the parasitic transmission of the tropical disease was understood in the beginning of the 20th century. As a therapeutic, antimony has been mostly used for the treatment of leishmaniasis and schistosomiasis. The major toxic side-effects of antimonials as a result of therapy are cardiotoxicity (~9% of patients) and pancreatitis, which is seen commonly in HIV and visceral leishmaniasis co-infections.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Response to chemotherapy in experimental visceral leishmaniasis: T cell-dependent but interferon-gamma- and interleukin-2-independent. | 1991 Mar |
|
[Visceral leishmaniasis and multiple organ failure]. | 1993 Dec |
|
Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral Leishmaniasis. | 1994 |
|
[Interferon gamma as an immunological strategy for the treatment of human leishmaniasis]. | 1994 |
|
Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. | 1994 Nov 15 |
|
Interleukin 6 during active visceral leishmaniasis and after treatment. | 1995 Oct |
|
[Clinical and pathogenetic features of exposure of workers to antimonate ore]. | 1996 |
|
Treatment of New World cutaneous and mucosal leishmaniases. | 1996 Sep-Oct |
|
Efficacy and Tolerability of Liposomal Amphotericin B (Ambisome) in the Treatment of Visceral Leishmaniasis in Brazil. | 1997 Oct |
|
Leishmaniasis of glans penis. | 1998 May |
|
Marked elevation of myocardial trace elements in idiopathic dilated cardiomyopathy compared with secondary cardiac dysfunction. | 1999 May |
|
[American cutaneous leishmaniasis in the Federal District]. | 1999 Sep-Oct |
|
Mucosal leishmaniasis: quantitative nasal cytology as a marker of disease activity and indicator of healing. | 2000 Jan |
|
[Hematologic characteristics of leishmaniasis]. | 2000 Jan-Feb |
|
Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation. | 2000 Nov |
|
Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. | 2000 Nov |
|
Leishmaniasis in Sudan. Mucosal leishmaniasis. | 2001 Apr |
|
Cutaneous leishmaniasis in an Italian woman: case report. | 2001 Jun |
|
Novel bicistronic retroviral vector expressing gamma-glutamylcysteine synthetase and the multidrug resistance protein 1 (MRP1) protects cells from MRP1-effluxed drugs and alkylating agents. | 2001 Sep 20 |
|
In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate. | 2002 May 2 |
|
Functional identification of ion binding sites at the internal end of the pore in Shaker K+ channels. | 2003 May 15 |
|
Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9. | 2004 Sep 24 |
|
Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam. | 2004 Sep 3 |
|
Classification of heavy-metal toxicity by human DNA microarray analysis. | 2007 May 15 |
|
Characterization and distribution of the selected metals in the scalp hair of cancer patients in comparison with normal donors. | 2007 Sep |
|
Cutaneous leishmaniasis with boggy induration and simultaneous mucosal disease. | 2009 Jan |
|
A case of visceral leishmaniasis in Oltenia region (Romania). | 2010 |
|
A case with two unusual findings: cutaneous leishmaniasis presenting as panniculitis and pericarditis after antimony therapy. | 2010 Mar |
|
[An adult case of visceral leishmaniasis in a province of Black-Sea region, Turkey]. | 2010 Oct |
|
Monitoring of intracellular nitric oxide in leishmaniasis: its applicability in patients with visceral leishmaniasis. | 2011 Jan |
|
Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML. | 2015 Sep 15 |
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
3349 (Number of products:23)
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
||
|
CFR |
21 CFR 862.3110
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
||
|
NCI_THESAURUS |
C1940
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID5023879
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
PRIMARY | |||
|
30304
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
PRIMARY | |||
|
30513
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
PRIMARY | |||
|
m1953
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB13110
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
PRIMARY | |||
|
D000965
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
PRIMARY | |||
|
1311407
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
PRIMARY | RxNorm | ||
|
5354495
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
PRIMARY | |||
|
508
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
PRIMARY | |||
|
100000077405
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
PRIMARY | |||
|
9IT35J3UV3
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
PRIMARY | |||
|
9IT35J3UV3
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
PRIMARY | |||
|
C95187
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
PRIMARY | |||
|
231-146-5
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
PRIMARY | |||
|
SUB12914MIG
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
PRIMARY | |||
|
7440-36-0
Created by
admin on Fri Dec 15 17:17:42 GMT 2023 , Edited by admin on Fri Dec 15 17:17:42 GMT 2023
|
PRIMARY |
ACTIVE MOIETY